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Background: MNGIE is a fatal inherited disease caused by mutations in the gene 
encoding thymidine phosphorylase, leading to reduced enzyme activity, systemic toxic 
accumulation of nucleosides and secondary mitochondrial DNA damage.  Enzyme 
replacement with EETP has demonstrated metabolic and clinical improvements in MNGIE 
in our compassionate treatment programme. 
Aims:  To determine the long-term safety, tolerability, pharmacodynamics and clinical 
efficacy of repeated doses of EETP in patients with MNGIE. 
Methods: This multi-centre, multiple dose study will be conducted in two parts: a 
double-blind, multiple-ascending dose phase (Part 1) of eight weeks and an open-label, 
multiple-dose phase (Part 2) of 24 months. We will recruit 12 patients who meet the 
following criteria: ≥ 18 years of age, a confirmed diagnosis of MNGIE and able to 
adequately grant informed consent. In Part 1, patients will be randomised to three 
dosing cohorts (20, 50 or 100 IU/kg) at a ratio of 3:1 to receive EETP or placebo. 
Patients randomised to placebo will receive two doses of placebo and then active drug 
for third and fourth dose on Day 28 and Day 42.  Collective safety and 
pharmacodynamics data will be reviewed from all 4 patients treated at each dose before 
dose escalation to the next cohort. Patients completing Part 1 will be entered into Part 2 
to receive EETP every 2 weeks, where the dose may be escalated where 
pharmacodynamics data indicates the patient has not achieved metabolic correction. 
Results: Mean laboratory values over time will be plotted by dose group. Descriptive 
statistics will be provided for clinical laboratory data, pharmacodynamics data and vital 
signs. Associations between pharmacodynamics parameters and clinical activity 
parameters will be explored. Data collection should be finalised by March 2020. 
Conclusions: Positive results from this trial will support a Marketing Authorisation 
Application for EETP and its therapeutic use in treating patients with MNGIE. 
 
 
